Sunshine Lake Pharma (HKG:6887) began trading at HK$57.50 on the Hong Kong bourse on Thursday, following its listing by introduction, after completing a merger with Yichang HEC Changjiang Pharmaceutical (HKG:1558).
The vertically integrated drugmaker's listing involved no fundraising.
A total of 112.7 million Sunshine Lake H-shares were admitted to trading on the main board, issued to HEC shareholders at a share exchange ratio of 0.263614 Sunshine Lake share for each HEC H-share cancelled.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。